Share Name Share Symbol Market Type Share ISIN Share Description
Convatec Group Plc LSE:CTEC London Ordinary Share GB00BD3VFW73 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05 -0.03% 183.05 5,878,365 16:35:12
Bid Price Offer Price High Price Low Price Open Price
183.45 183.65 185.05 179.90 182.15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1,436.66 157.77 8.63 21.6 3,572
Last Trade Time Trade Type Trade Size Trade Price Currency
17:44:23 O 8,202 183.552 GBX

Convatec (CTEC) Latest News

More Convatec News
Convatec Takeover Rumours

Convatec (CTEC) Share Charts

1 Year Convatec Chart

1 Year Convatec Chart

1 Month Convatec Chart

1 Month Convatec Chart

Intraday Convatec Chart

Intraday Convatec Chart

Convatec (CTEC) Discussions and Chat

Convatec Forums and Chat

Date Time Title Posts
06/8/201909:47ConvaTec - placing at 225p363

Add a New Thread

Convatec (CTEC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Convatec trades in real-time

Convatec (CTEC) Top Chat Posts

DateSubject
20/10/2019
09:20
Convatec Daily Update: Convatec Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker CTEC. The last closing price for Convatec was 183.10p.
Convatec Group Plc has a 4 week average price of 171.85p and a 12 week average price of 148.65p.
The 1 year high share price is 191.15p while the 1 year low share price is currently 113.25p.
There are currently 1,951,472,651 shares in issue and the average daily traded volume is 5,727,143 shares. The market capitalisation of Convatec Group Plc is £3,572,170,687.66.
22/1/2019
10:08
robow: One of Peel Hunt's stock picks for 2019 Convatec (CTEC) The depressed share price at medical products company Convatec has led to a rise in the dividend yield but the poor sentiment is unfounded. Analyst Amy Walker retained her ‘hold’ recommendation and target price of 170p on the stock. She said that ‘low visibility on earnings momentum has depressed the share price, leading to a rise in the dividend yield’ but even if the group misses her ‘conservative’ growth forecasts by 7% to 11% the company could still ‘yield at least 3% at the current share price, at the bottom of its target pay-out range’. Walker is not pessimistic about the outlook for the company, stating that the demand for the medical technology firm’s products were ‘unlikely to change materially from their mid-single digit market growth rates’. She added that the company can ‘support a stable to growing dividend’ but the most likely driver of volatility is the share price ‘which declined more than 30% on the most recent profit warning’.
30/10/2018
09:55
philanderer: Numis upgrades Convatec to ‘buy’ Numis has upgraded medical technology company Convatec (CTEC) after an ‘unwarranted’ 35% fall in the share price. Analyst Paul Cuddon upgraded his recommendation from ‘hold’ to ‘buy’ with a target price of 220p on the shares, which jumped 5.6% to 155p yesterday. ‘We do not think the loss of a chief executive and the decline in infusion devices warranted a 35% fall in Convatec’s share price, especially when the broader chronic care business is maintaining consistent 2% quarterly growth,’ he said. ‘We see full-year 2018 results, details on the self-help strategy and full-year 2019 outlook as key catalysts. The company trades on 10x enterprise value/earnings and offering sector leading free cashflow yield and so we upgrade to “buy”.’ HTTPS://citywire.co.uk/money/the-expert-view-just-eat-hsbc-and-iag/a1170201?re=59360&ea=290170&utm_source=BulkEmail_Money_Daily&utm_medium=BulkEmail_Money_Daily&utm_campaign=BulkEmail_Money_Daily#i=6
16/10/2018
08:25
robow: from Citywire Buying opportunity at Convatec, says Numis Medical technology company Convatec (CTEC) has delivered a poor third statement but the heavy share price fall could present a buying opportunity. The shares tumbled 34% to 148.2p yesterday after the company issued a profit warning and announced the departure of chief executive Paulk Moraviec. Analyst Paul Cuddon retained his ‘hold’ recommendation and target price of 220p on the shares. ‘Ultimately the statement reads poorly, but on our first take, the earnings per share downgrade is just 5% and should the shares fall materially we could see an interesting buying opportunity with the performance of the chronic care business showing continued steady growth,’ he said.
15/10/2018
20:46
cantrememberthis2: Despite the warning and its cautious stance on the stock, RBC said the share price reset has gone too far and highlighted the fact that Convatec is still a cash generative business with attractive qualities. "We would remind investors that Convatec is still a highly cash generative business, and at the current share price is generating a free cash flow yield of over 7%, with a dividend yield of 3%," it said. "With the performance wanting we would hope all options are now on the table to maximise shareholder value."
15/10/2018
13:49
seastork: Very poor reaction to today's news and a tad over-kill in current conditions. Trading update was disappointing, CEO retiring and dividend payout day has seen a perfect storm to bash the share price. Hindsight is always 20/20 and more bad news might be in the pipeline. But fundamentals are good, expertise in the market with consumable products and long-term customer base. Taken the opportunity to top-up from here.
23/10/2017
13:28
analyzer: Daily Mail/This is Money : 19 October 2017 DIRECTOR'S DEALS: Convatec chairman Sir Christopher Gent buys nearly £83,000 worth of shares City grandee Sir Christopher Gent spent nearly £83,000 buying shares in Convatec after it lost more than a fifth of its value in a day. In a vote of confidence in the medical products firm, the chairman bought 38,889 shares at 213p. That followed a 26.6 per cent slump in the share price on Monday, after Convatec slashed its sales forecasts for the year amid supply issues and disappointing revenues. Gent is a former chief executive of Vodafone and an ex-chairman of GlaxoSmithKline. Read more: http://www.thisismoney.co.uk/money/markets/article-4998318/DIRECTOR-S-DEALS-Convatec-chairman-Sir-Christopher-Gent.html#ixzz4wKkFv63p
05/5/2017
10:03
anley: Just as I expected and what is more this business has really only started so expect growth in Margins.....Sales and some more productivity gains such as moving a factory from USA to offshore...........Donald wont like that!! Share price is down as the general market is and with more free shares and not all the institutions in the market price will consolidate and then move slowly forward. A very good management team in place and that is what one needs to look for in todays markets and Brexit about to get a bother...........
Convatec share price data is direct from the London Stock Exchange
Your Recent History
LSE
CTEC
Convatec
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191020 10:35:07